Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01302600
Recruitment Status : Completed
First Posted : February 24, 2011
Last Update Posted : November 22, 2016
Association Française contre les Myopathies (AFM), Paris
Information provided by (Responsible Party):
Hoffmann-La Roche

February 18, 2011
February 24, 2011
November 22, 2016
November 2010
October 2013   (Final data collection date for primary outcome measure)
Motor Function Measure [ Time Frame: every 6 months ]
Motor function Measure (MFM) D1+D2 score
Motor Function Measure [ Time Frame: every 6 months ]
Motor fonction Measure (MFM) D1+D2 score
Complete list of historical versions of study NCT01302600 on Archive Site
responder analyses on MFM and HFMS, time to 4 point decrease on HFMS, CMAP/MUNE, PedsQL, FVC, CGI and safety [ Time Frame: every 3 months ]
Same as current
Not Provided
Not Provided
Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Years SMA Patients.
Phase II, Multicenter, Randomized, Adaptive, Double-blind, Placebo Controlled Study to Assess Safety and Efficacy of Olesoxime (TRO19622) in 3-25 Year Old Spinal Muscular Atrophy (SMA) Patients.
Assess the efficacy and the safety of olesoxime in SMA type 2 or type 3 non ambulant patients aged 3-25 years

This study is a multicenter, double-blind, randomized, adaptive, parallel groups, placebo controlled 3-stage study in patients with SMA type 2 or non ambulant type 3.

Stage 1 DMC 3-month safety assessment: An independent Data Monitoring Committee (DMC)will assess the safety of olesoxime every 3 months.

Stage 2 Efficacy/futility analyses at one year: A first interim efficacy analysis will be performed after all patients have been treated for one year (52 weeks) in order to assess the need to continue the study to reach the planned objective. In the event of positive and significant results in favor of olesoxime, the study will be considered as successful and all patients will be switched to olesoxime to allow the assessment of the sustainability of the treatment effect and safety. If the results are significantly in favor of placebo, the study will be discontinued for failure (futility).

Stage 3 Efficacy and safety analysis at two years: The expected study duration is of 2 years (104 weeks) to show efficacy. If the study is not discontinued for futility or medication regimen is changed due to success, the study will therefore continue until planned completion i.e. 104 weeks.

Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Spinal Muscular Atrophy Type II
  • Spinal Muscular Atrophy Type III Non Ambulant
  • Drug: Olesoxime
    Liquid suspension formulation, 100 mg/ml at a dose of 10 mg/kg will be administered once a day with food at dinner
  • Drug: Placebo
    0.1ml/kg once a day with food at dinner.
  • Experimental: Olesoxime
    100 patients in this arm. liquid suspension
    Intervention: Drug: Olesoxime
  • Placebo Comparator: Placebo
    50 patients enrolled in this arm. liquid suspension
    Intervention: Drug: Placebo
Bertini E, Dessaud E, Mercuri E, Muntoni F, Kirschner J, Reid C, Lusakowska A, Comi GP, Cuisset JM, Abitbol JL, Scherrer B, Ducray PS, Buchbjerg J, Vianna E, van der Pol WL, Vuillerot C, Blaettler T, Fontoura P; Olesoxime SMA Phase 2 Study Investigators. Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017 Jul;16(7):513-522. doi: 10.1016/S1474-4422(17)30085-6. Epub 2017 Apr 28.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
October 2013
October 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Weakness and hypotonia consistent with a clinical diagnosis of spinal muscular atrophy (SMA) type II or III
  • Laboratory documentation of homozygous absence of SMNI exon 7 and/or deletion and mutation on other allele
  • MFM relative score (percentage of the maximum sum of both dimensions) >= 15% (D1 + D2 score)
  • HFMS score at baseline >= 3
  • Non ambulant patients defined as patients with HFMS score =< 38
  • Must be 3 years of age or older, but younger than 26 years of age, at time of enrolment
  • Age of onset of symptoms =< 3 years of age
  • Signed informed consent of patient and/or parents/guardian
  • Laboratory results drawn within 31 days prior to start of study entry demonstrating no clinically significant abnormalities
  • Ability to take the study treatment (tested at screening after informed consent)

Exclusion Criteria:

  • Evidence of renal dysfunction, blood dysplasia, hepatic insufficiency, symptomatic pancreatitis, congenital heart defect, known history of metabolic acidosis, hypertension,significant central nervous system impairment, or neurodegenerative or neuromuscular disease other than SMA
  • Any clinically significant ECG abnormality
  • Any acute co-morbid condition interfering with the well-being of the subject within 7 days of enrolment including bacterial infection, viral infectious processes, food poisoning, temperature > 37.0 °C, the need for acute treatment or observation due to any other reason, as judged by the investigator; patient can be included after resolution of the acute event
  • Use of medications intended for the treatment of SMA including riluzole, valproic acid, hydroxyurea, sodium phenylbutyrate, butyrate derivatives, creatine, carnitine, growth hormone, anabolic steroids, probenecid, oral or parenteral use of corticosteroids at entry, agents anticipated to increase or decrease muscle strength or agents with known or presumed histone deacetylase (HDAC) inhibition, within 30 days prior to study entry. Subjects who use a nebulizer or require an inhaler to steroids will be allowed in the study; however oral use of steroids is prohibited. The oral use of salbutamol is permitted with the following restrictions: patients should have been on salbutamol for at least 6 months before inclusion in the trial, with good tolerance. The dose of salbutamol should remain constant for the duration of the trial. The use of inhaled beta-agonists (for the treatment of asthma crisis for example) is allowed.
  • Spinal rod or fixation for scoliosis within the past 6 months or anticipated need of rod or fixation within 6 months of enrolment.
  • Inability to meet study visit requirements or cooperate reliably with functional testing
  • Coexisting medical conditions that contraindicate travel, testing or study medications
  • Olesoxime is contraindicated in subjects/patients who develop drug hypersensitivity to it or one of the formulation excipients including hypersensitivity to sesame oil.
  • Patients with hemostasis disorders
  • Patients with known biliary tract obstruction
  • Current or planned pregnancy or nursing period
  • For Women: Failure to use one of the following safe methods of contraception:

    1. Female condoms, diaphragm or coil, each used in combination with spermicides
    2. Intra-uterine device
    3. Hormonal contraception in combination with a mechanical method of contraception
  • Participation in any other investigational drug or therapy study within the previous 3 months.
Sexes Eligible for Study: All
3 Years to 25 Years   (Child, Adult)
Contact information is only displayed when the study is recruiting subjects
Belgium,   France,   Germany,   Italy,   Netherlands,   Poland,   United Kingdom
TRO19622 CL E Q 1275-1 ( Other Identifier: Trophos ID )
Not Provided
Not Provided
Hoffmann-La Roche
Hoffmann-La Roche
Association Française contre les Myopathies (AFM), Paris
Principal Investigator: Enrico Bertini, MD Bambino Gesu Hospital
Hoffmann-La Roche
November 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP